Who We Are
As the world's leading provider of generic drugs, Teva Pharmaceuticals understands the importance of making safe, quality medications accessible —and affordable.
At Teva, we continually evaluate and pursue growth opportunities that advance our goal of being a stronger, more diversified organization with the scale and resources to drive value across our business today and in the future. With the acquisition of Actavis Generics, our combined company will offer the richest product pipeline in the generic industry and will continue to lead the way with complementary technologies and product portfolios, offering more differentiated and durable products than any other generic company of this scale. Learn more about the acquisition.
One in eight of the 3.88 billion generic prescriptions written in the United States is filled with a Teva product.1 Teva helped contribute to the $254 billon dollars in savings in U.S. healthcare by providing affordable generic drugs!2
Teva's extensive U.S. operations include more than 9,500 employees in more than 30 facilities across the United States and its Territories.3 With a portfolio of more than 1,800 molecules, Teva produces a wide range of generic products in nearly every therapeutic area.
Teva Pharmaceuticals USA is a wholly owned subsidiary of Israeli-based Teva Pharmaceutical Industries Ltd., the global leader in generics and one of the world's leading pharmaceutical companies.
Learn more about our history and how we have grown to be the leading provider of generic drugs.
Choosing Teva Generics is choosing to enjoy the benefits only Teva can provide. Learn more about our advantages.
1. IQVIA NPA Data (as of MAT December 2018) on file at Teva.
2. Generic Pharmaceutical Association. Generic Drug Savings in the U.S. Seventh Annual Edition: 2015.http://www.gphaonline.org/media/wysiwyg/PDF/GPhA_Savings_Report_2015.pdf. Accessed July 19, 2016
3. Internal Data on File